推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to light brown
溶解度
DMSO: 2 mg/mL, clear (warmed)
儲存溫度
−20°C
SMILES 字串
[H]Cl.OC(C1=CN(C2CC2)C3=C(Cl)C(N4CCCCC(N)C4)=C(F)C=C3C1=O)=O
生化/生理作用
Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic.
Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic. Besifloxacin is effective against gram positive and negative, aerobic and anerobic bacteria. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis. Besifloxacin inhibits both DNA gyrase and topoisomerase IV at nearly equal concentrations. It is used clinically primarily in the treatment of bacterial conjunctivitis.
Besifloxacin stops the production of pro-inflammatory cytokines in vitro.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Clinical ophthalmology (Auckland, N.Z.), 4, 215-225 (2010-05-14)
Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in
Cornea, 34(8), 967-971 (2015-06-16)
To present the clinical outcome of 3 cases of ocular surface infections by Mycobacterium chelonae treated with besifloxacin (0.6%, Besivance; Bausch & Lomb, Tampa, FL). In this retrospective review of a small case series, we reviewed the medical records of
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 50(3), 184-191 (2015-06-05)
Acute bacterial conjunctivitis is a common infection of the ocular surface. Increasing rates of bacterial resistance have prompted the development of new antibiotics with improved activity against the bacterial species most often found in this disease. Besifloxacin is the first
Synthetic approaches to the 2009 new drugs
Bioorganic & Medicinal Chemistry, 19(3), 1136-1154 (2011)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门